Pidsr Cif

Download as pdf or txt
Download as pdf or txt
You are on page 1of 17

Philippine Integrated Disease

Surveillance and Response

Republic Act 3573 (Law of Reporting of Communicable


Diseases), requires all individuals and health facilities to
report notifiable diseases to local and national public health authorities.

Weekly Notifiable Disease Report


Summary Page
Name of Disease Reporting Unit : _________________________________________________________________
Type of facility: Govt Hospital Private Hospital Rural Health Unit Clinic
City Health Office Govt Laboratory Private Laboratory Seaport/Airport
Address: ____________________________________________________________ Tel. No.______________
This report was prepared by: _____________________________________________ Date: ____/____/____
(Signature over printed name)
This report was submitted to
(Name of RHU/CHO/PHO/CHD): __________________________________________ Date: ____/____/____
This report was approved by: ______________________________________________ Date: ____/____/____
(Name & Signature of Head of office/unit/hospital/clinic)

List of Notifiable Diseases/Syndromes


Indicate the number of case/s in the corresponding line for case/s of disease/
syndrome seen and 0 if no cases seen.
Category I (Immediately Notifiable)

Category II (Weekly Notifiable)

_____ Acute Flaccid Paralysis

_____ Acute Bloody Diarrhea

_____
_____
_____
_____
_____
_____
_____

_____
_____
_____
_____
_____
_____
_____

Acute Encephalitis Syndrome


Acute Hemorrhagic Fever Syndrome
Acute Viral Hepatitis
Bacterial Meningitis
Cholera
Dengue
Diphtheria

_____
_____
_____
_____
_____
_____

Influenza-like Illness
Leptospirosis
Malaria
Non-neonatal Tetanus
Pertussis
Typhoid and Paratyphoid Fever

Adverse Event Following Immunization (AEFI)


Anthrax
Human Avian Influenza
Measles
Meningococcal Disease
Neonatal Tetanus
Paralytic Shellfish Poisoning

_____ Rabies
_____ Severe Acute Respiratory Syndrome
(SARS)
_____ Outbreaks
Clusters of diseases

Unusual diseases or threats

Category I: Notify simultaneously the PHO, CHD and NEC within 24 hours of detection and send advance copy of
the Case Investigation Form (CIF) as soon as possible.
Category II: Report all cases of notifiable diseases/syndromes every FRIDAY of the week to the next higher level
using the Case Report Form (CRF).
Reminder: Submission of report is every FRIDAY of the week. The weekly report should include this page (Summary Page) ,
Case Investigation Forms (CIF) and the Case Report Forms (CRF).

Lets help prevent epidemics

Page 1 of 2
Philippine Integrated Disease
Surveillance and Response

Case Investigation Form

Acute Flaccid Paralysis


Name of DRU:

Type: RHU

CHO Govt Hospital

Govt Laboratory

Address:

I. PATIENT
INFORMATION:

Patient Number:

Patients First Name

Private Laboratory

Middle Name

Complete Address:

Male
Sex:
Female

ILHZ:

Patient Admitted? Yes No Unknown


MM

Clinic

Airport/Seaport
Last Name

MM

District:

Private Hospital

DD

YY

Age:

Date of
Birth:

Days
Months
Years

MM

DD

YY

MM

DD

YY

Deep
Tendon
Reflexes

Motor
Status

Date Admitted/ Seen/Consult


DD

YY

Date of Report:

Date of Investigation:

II. CLINICAL DATA (Put a check [ v ] in the appropriate box)

PRODROME

Fever: Y N U
Cough: Y N U
Diarrhea/Vomiting:
Y N U
Muscle pain:
Y N U
Meningeal signs:
Y N U

PARALYSIS

SITE OF FLACCID PARALYSIS

Sensory
Status

Date onset: _____/_____/_____


Present at birth?: Y N U
Asymmetric?:
Y N U

Right arm: Y N U

_____________ _____________ ____________

Left arm:

Y N U

_____________ _____________ ____________

Right leg:

Y N U

_____________ _____________ ____________

PROGRESSION
Paralysis fully developed within 3
to 14 days from onset of illness?
Y N U

Left leg:

Y N U

_____________ _____________ ____________

Direction of paralysis:
Ascending Descending
Unknown

Breathing muscles: Y N U

NOTE: Instructions on the grading/


scoring of the sensory status, deep
Facial muscles:
Y N U tendon reflexes and motor status are
Working Diagnosis : ____________ presented at the back of this page.
Neck muscles:

Y N U

_____________________________

III. EPIDEMIOLOGIC DATA


History of neurologic disorder?: Y N U

If YES, specify disorder:_________________________________

Did the patient travel (>10 km from house) one month prior to illness? Y N U
If YES, specify place:____________________________________

Date traveled: From_____/_____/_____ To _____/_____/_____

Other AFP cases in patients community within 60 days of patients paralysis? Y N U


Does the patient had any history of injection, trauma and/ or animal bite ? Y N U
If YES, specify type _______________

IV. IMMUNIZATION HISTORY


Total OPV doses received: _______

Date last dose of OPV : _____/_____/_____

Is this a Hot case? Y N

V. LABORATORY DATA
Stool
sample #

Collected?

If YES, date
taken

Date sent to
Date received RITM
RITM

Y N

___/___/___

___/___/___

Y N

___/___/___

___/___/___

Adequate? Y N

Result

Date result

___/___/___

NEG 1 2 3 NPEV
Other, specify______________________

___/___/___

___/___/___

NEG 1 2 3 NPEV
Other, specify______________________

___/___/___

Other Information (Stool specimen):

VI. 60-DAY FOLLOW-UP


Expected date of follow -up:_____/_____/_____ Actual date of follow -up conducted:_____/_____/_____
P.E. done? Y N

If NO, reason for no examination: Patient died Lost to follow -up Other, specify____________________

Residual paralysis at 60 days?: Y N U

Atrophy?: Y N U

Other observations:_____________________________________________

175

Page 2 of 2

Case Investigation Form

Acute Flaccid Paralysis


VII. CLASSIFICATION (TO BE FILLED UP BY THE EXPERT PANEL ONLY)
FINAL CLASSIFICATION
Confirmed wild polio
Vaccine-derived paralytic polio (VDPV)
Vaccine-associated paralytic polio (VAPP)
Polio compatible
Discarded
Not AFP
Sabin-like
Date classified: _____/_____/_____

IF VAPP
Recipient VAPP
Contact VAPP
Unknown

CLASSIFICATION CRITERIA

FINAL DIAGNOSIS

Laboratory
EPI linked
Lost to follow -up
Death
With residual paralysis
Without residual paralysis

AFP Case definition:

Any child less than 15 years of age with acute flaccid paralysis, OR
A person of any age in whom poliomyelitis is suspected by a physician.

Hot Case Description:

An AFP case that is <5 years old with < 3 doses of OPV and has fever at the onset of asymmetrical paralysis,
OR
An AFP case or a person of any age whose stool specimen(s) has poliovirus isolate.

Grading/Scoring of Sensory Status, Deep Tendon Reflexes and Motor Status:


A. Sensory status is presented in percentage and categorized as follows:

= 25% = Absent

= 25% but <100% = Reduced

100% = Normal

B. Deep tendon reflexes (DTRs) are presented in (+) symbol and categorized as follows:

none or 0 = absent

++ = normal

+++ with/without clonus = increased or exaggerated

= reduced

C. Motor status is presented in fraction and categorized as follows:

0/5 = absent or no movement

1/5 to 3/5 = reduced movement (with movement but not against resistance or gravity)

4/5 to 5/5 = normal (movement with full resistance and against gravity)

176

Page 1 of 2

Case Investigation Form

Philippine Integrated Disease


Surveillance and Response

Anthrax
(ICD 10 Code: A22)

Name of DRU:
Type: RHU
Address:

CHO Govt Hospital

Govt Laboratory
Patient Number:

I. PATIENT
INFORMATION:

Patients First Name

Private Laboratory

Middle Name

Male
Sex:
Female

Clinic

Airport/Seaport
Last Name

MM

Complete Address:

District:
Occupation:

Private Hospital

DD

YY

Age:

Days
Months
Years

Date of
Birth:

ILHZ:
Name Workplace:
Address of Workplace:

II. CLINICAL
INFORMATION:

Signs and
Symptoms:

Admitted?
Yes No Unknown

Fever
Upset stomach (nausea)
Headache
Dry cough
Sore throat
Trouble swallowing
Trouble breathing

Date Admitted/
Seen/Consult

MM

DD

Stomach pain
Vomiting blood
Bloody diarrhea
Sweating excessively
Extreme tiredness
Pain or tightness in the chest
Sore muscles

YY

Date Onset of
Illness

MM

DD

YY

Neck pain
Itchy skin
Black scab on skin
Skin lesions
Describe lesion: ____________
_________________________

Other (list): ________________


_________________________

III. POTENTIAL RISK FACTORS IN THE 15-60 DAYS PRIOR TO ONSET OF SIGNS/SYMPTOMS
Y N U

Is the patients occupation associated with animals or agriculture?

Y N U

Has the patient been exposed to Anthrax Vaccine or to anthrax -vaccinated animals?

Y N U

Does the patient have occupational or other exposure to hides, wool, furs, bone meal or other animal products?

Y N U

Contact with live or dead animals? (cattle, sheep, goats, horses, pigs and other herbivores both livestock and wildlife)

Y N U

Does the patient have a history of travel beyond his/her usual place of residence/surroundings?

Y N U

Does the patient work in a laboratory?

Y N U

Have any household members experienced similar symptoms recently?

Y N U

Has the patient eaten undercooked meat? (cattle, sheep, goats, horses, pigs and other herbivores both livestock and wildlife)

Y N U

Did the patient receive unusual letters or packages? (e.g. containing threats or unusual messages)

Y N U

Has the patient opened mails for others?

Y N U

Was the patient present or nearby when an envelope that contained any form of powder was opened?

IV. CLINICAL FORMS, CLASSIFICATION AND OUTCOME:


CLINICAL FORMS

CASE CLASSIFICATION

OUTCOME

Cutaneous
Gastrointestinal

Suspected Case

Alive

Pulmonary

Probable Case

Died,

Meningeal

Confirmed Case

Unknown

Unknown

Date died: ____/____/____

V. LABORATORY TESTS:
Specify
Specimen

If YES, date
taken
MM

MM

DD

DD

Type of laboratory
test done

Results
N=Negative; I=Indeterminate; U-Unknown

YY

Positive for:

N I U

Positive for:

N I U

YY

Date result
MM

DD

YY

MM

DD

YY

179

Page 2 of 2

Case Investigation Form

Anthrax

CASE DEFINITION/CLASSIFICATION:

Suspected case: A person with acute onset of illness characterized by several clinical forms as follows:
a. localized form:
1. cutaneous: skin lesion evolving over 1 to 6 days from a papular through a vesicular stage, to a depressed
black eschar invariably accompanied by edema that may be mild to extensive;
b. systemic forms:
1. gastro-intestinal: abdominal distress characterized by nausea, vomiting, anorexia and followed by fever;
2. pulmonary (inhalation): brief prodrome resembling acute viral respiratory illness, followed by rapid onset of
hypoxia, dyspnea and high temperature, with X-ray evidence of mediastinal widening;
3. meningeal: acute onset of high fever possibly with convulsions, loss of consciousness, meningeal signs and
symptoms; commonly noted in all systemic infections;

AND has an epidemiological link to a suspected or confirmed animal cases or contaminated animal products;

Probable case: A suspected case that has a positive reaction to allergic skin test (in non-vaccinated individuals);

Confirmed case: A suspected case that is laboratory-confirmed.

LABORATORY CONFIRMATION:

Isolation of Bacillus anthracis from a clinical specimen (e.g., blood, lesions, discharges)

Demonstration of B. anthracis in a clinical specimen by microscopic examination of stained smears (vesicular fluid,

blood, cerebrospinal fluid, pleural fluid, stools)


Positive serology (ELISA, Western blot, toxin detection, chromatographic assay, fluorescent antibody test (FAT))

180

Page 1 of 2
Philippine Integrated Disease
Surveillance and Response

Case Investigation Form

Measles
(ICD 10 Code: B05)
Name of DRU:
Type: RHU

Address:

CHO Govt Hospital

Govt Laboratory

I. PATIENT
INFORMATION:

Patient Number:

Patients First Name

Middle Name

Complete Address:

MM

DD

MM

Date Admitted/
Seen/Consult

YY

Date of Report:

Male
Female

MM

DD

Age:

YY

Days
Months
Years

Date of
Birth:

DD

YY

DD

Clinic

Airport/Seaport

Last Name
MM

Sex:
District:
ILHZ:
Patient Admitted? Yes No Unknown

Private Hospital

Private Laboratory

MM

Date Onset
of Illness

DD

YY

YY

Date of Investigation:

II. CLINICAL INFORMATION:

III. VITAMIN A AND VACCINATION HISTORY:


Was the patient given therapeutic Vitamin A during this illness?:
oY oN oU
Patient received routine measles vaccination? o Y o N o U
No. of doses received:_______ Date of last vaccination:____/___/____

Fever: o Y o N o U Date onset:____/____/____


Rash: o Y o N o U Date onset:____/____/____
Cough: o Y o N o U

If NO, state the reasons:


o Mother was busy o Child was sick o Forgot the schedule
o No vaccine available o Against belief

Runny nose/coryza: o Y o N o U
Red eyes/conjunctivitis: o Y o N o U

o Not eligible for vaccination o Medical contraindication


o Fear of side effects
Other reasons, specify:__________________________________

Other symptoms: ___________________________________


_________________________________________________
Are there any complications?

oY oN o U

If YES, specify: ____________________________________

Patient received vaccination during special campaigns? o Y o N o U

IV. EXPOSURE HISTORY:


Is there a history of travel to an area with known measles transmission 7-18 days prior to the appearance of rash?
Where did exposure probably occur?
o Day care
o Home/ dormitory
o School

oY o N o U

o Health Care Facilities o Community


o Unknown
o Other, specify _______________________
Was there contact with a laboratory confirmed Measles case 7-18 days prior to rash onset? o Y o N o U
Are there other measles cases in the community? o Y o N o U

V. LABORATORY TESTS:
Collected?

If YES, date
taken

Serum

Y N

___ /___ /___ ___ /___ /___ ___ /___ /___

___ /___ /___

Dried blood

Y N

___ /___ /___ ___ /___ /___ ___ /___ /___

___ /___ /___

NP swab

Y N

___ /___ /___ ___ /___ /___ ___ /___ /___

___ /___ /___

Urine

Y N

___ /___ /___ ___ /___ /___ ___ /___ /___

___ /___ /___

NP aspirate

Y N

___ /___ /___ ___ /___ /___ ___ /___ /___

___ /___ /___

Throat swab

Y N

___ /___ /___ ___ /___ /___ ___ /___ /___

___ /___ /___

Specimen

Date sent to
RITM

Date received RITM

Measles IgM Result

Rubella IgM Result

Date result

VI. CLASSIFICATION AND OUTCOME:


CASE CLASSIFICATION

OUTCOME

Laboratory Confirmed

Alive

Epidemiologically-linked

Died

Clinically-confirmed

Unknown

FINAL DIAGNOSIS

Date died: ____/____/____

Discarded Case

181

Page 2 of 2

Case Investigation Form

Measles

CASE DEFINITION/CLASSIFICATION:

Suspected

Laboratory-confirmed case: Suspected case that is laboratory-confirmed.

Epidemiologically-linked: An epidemiologically-linked measles case is defined as a suspected measles


case who was not discarded and who:
had contact with another epidemiologically-linked case or a laboratory confirmed case 7-21
days before rash onset and
the other epidemiologically-linked or laboratory confirmed case was infectious at the time of
contact (i.e., contact was 4 days before to 4 days after rash onset in the other epidemiologically-linked or laboratory confirmed case)

Clinically-confirmed: A suspected measles case, that, for any reason, is not completely investigated*
(e.g. death before investigation, no blood sample) or has equivocal laboratory test results.

case: Any individual, regardless of age, with the following signs and symptoms:
history of fever (38C or more) or hot to touch; and
generalized non-vesicular rash of 3 or more days duration; and,
at least one of the following: cough, coryza, or conjunctivitis

*Such cases represent failures of the surveillance system to adequately classify a case

Discarded or not measles case: A suspected measles case with an adequate specimen that is not
serologically confirmed or is confirmed positive for other diseases such as rubella or dengue.

LABORATORY CONFIRMATION:

Positive serologic test result for anti-measles IgM antibodies


Fourfold rise in anti-measles IgG antibodies in acute and convalescent serum
Isolation of measles virus
Dot immunobinding assay
Polymerase chain reaction testing for measles nucleic acid

Therapeutic Dosage of Vitamin A for Measles cases:

50,000 IU for children <6 months old


100,000 IU for children 6 to 11 months old
200,000 IU for children 12 to 71 months old

Note: The therapeutic dosage of Vitamin A for measles cases should be given upon diagnosis regardless of
when the last dose of vitamin A capsule was given.

182

Page 1 of 2

Philippine Integrated Disease


Surveillance and Response

Case Investigation Form

Meningococcal Disease
(ICD 10 Code: A39)
Name of DRU:
Type: RHU
Address:

CHO Govt Hospital

Govt Laboratory
Patient Number:

I. PATIENT
INFORMATION:

Patients First Name

Private Laboratory

Middle Name

Sex:

Male
Female

Clinic

Airport/Seaport
Last Name

MM

Complete Address:

District:

Private Hospital

DD

YY

Age:

Days
Months
Years

Date of
Birth:

ILHZ:

Occupation:

Name Workplace:
Address of Workplace:

Name of School:

Address of School:

If student:
Admitted?
II. CLINICAL
INFORMATION: Yes No

Signs and
Symptoms:

Unknown

Fever
Headache
Maculopapular rash
Petechia
Purpura
Other lesions:

Clinical Presentation:
Meningitis
Septicemia
Both

Date Admitted/
Seen/Consult

MM

DD

Seizure
Stiff neck
Vomiting
Change of sensorium
Drowsiness
Other signs / symptoms:

Case Classification:
Suspected Case
Probable Case
Confirmed Case

YY

Date Onset
of Illness

MM

DD

YY

Malaise
Cough
Sore throat
Runny nose
Dyspnea
Outcome:
Alive
Died, Date Died _____/_____/_____
Unknown

III. CASE
Were blood/CSF extracted before the first dose of antibiotics was given to the patient?
MANAGEMENT:

Yes No Unknown

What antibiotics were given in the hospital?

IV. LABORATORY TESTS:


Specimen

If YES, date
taken
MM

DD

Type of laboratory
test done

YY

Positive for:

N I U ND

Latex agglutination Positive for:

N I U ND

Gram stain

N I U ND

Culture
MM

DD

YY

CSF
MM

MM

Blood

DD

DD

Results
N=Negative; I=Indeterminate; U-Unknown; ND= Not Done

YY

Positive for:

YY

Culture

Positive for:

Date result
MM

DD

YY

MM

DD

YY

MM

DD

YY

MM

DD

YY

N I U ND

183

Page 2 of 2

Case Investigation Form

Meningococcal Disease
V. PAST HISTORY: Did the PATIENT or CLOSE CONTACT/S interact with a suspected or confirmed meningococcal case
within 2 weeks before onset of illness?

Yes, the patient Yes, close contact/s (name/s) __________________________________________


If yes, what was the name of the suspected or confirmed meningococcal case?

What is the address of the suspected or confirmed meningococcal case?

Where did the patient or close contact/s interact with the meningococcal case?

Did the PATIENT travel within 2 weeks prior to illness?

When? MM/DD/YY

Number of Days?

If yes, where?

Yes No Unknown
Did a CLOSE CONTACT/S of the patient travel within 2 weeks prior to illness? If yes, who and where?

Yes No Unknown
Did the PATIENT attend any social gathering within 2 weeks prior to illness?

If yes, where?

Yes No Unknown
Did the PATIENT have upper respiratory tract infection within 2 weeks prior to illness? Yes

No Unknown

Did a CLOSE CONTACT/S have upper respiratory tract infection within 2 weeks prior to the patients illness?

Yes No Unknown,

If Yes, who?

CASE DEFINITION/CLASSIFICATION:

Suspected case: A person with sudden onset of fever (>38.5C rectal or >38.0C axillary) and one or more
of the following:
neck stiffness
altered consciousness
other meningeal signs
petechial or purpural rash
Note:

In patients <1 year, suspect meningitis when fever is accompanied by bulging fontanels

Probable case: A suspected case as defined above AND with Turbid cerebrospinal fluid (with or without
positive Gram stain) OR ongoing epidemic and epidemiological link to a confirmed case.

Confirmed case: A suspected OR probable case with laboratory confirmation.

LABORATORY CONFIRMATION:

Positive cerebrospinal fluid (CSF) antigen detection or culture.


Positive blood culture.

184

Page 1 of 2
Philippine Integrated Disease
Surveillance and Response

Case Investigation Form

Neonatal Tetanus
Name of DRU:
Type: RHU
Address:

CHO Govt Hospital

Govt Laboratory
Patient Number:

I. PATIENT
INFORMATION:

Patients First Name

Middle Name

Complete Address:

MM

DD

YY

Date of Report:

MM

Date Admitted/
Seen/Consult
MM

DD

Age in days:

YY

Date of
Birth:

DD

DD

Clinic

Airport/Seaport
Last Name

MM

Male
Female

Sex:
District:
ILHZ:
Patient Admitted? Yes No Unknown

Private Hospital

Private Laboratory

YY

YY

Date of Investigation:

Date Onset of
Illness
Mothers Full Name:

MM

DD

YY

II. CLINICAL DATA:


In the first 2 days of life did the baby suck and cry normally?

After 2 days of life, did the baby have convulsions (stiffness or fits)?

Yes No Unknown

Yes No Unknown

After 2 days of life, was the baby unable to suck?

Was the umbilical stump infected? (bad smell, pus)

Yes No Unknown

Yes No Unknown

III. MOTHERS INFORMATION:


Prenatal Care

Immunization Status

If she has a card, copy the dates of all

No. of total pregnancies:_____

TT immunizations recorded on the

Live births:_____ Living children:______

How many doses of TT has the mother re-

card:

ceived?_____ doses

TT1:_____/_____/_____

____unknown

How many prenatal care visits did the mother


make to a health facility during her pregnancy?
______
When was the first prenatal visit?___/____/___

Date last dose given:_____/____/_____


If she received 2 doses, were they given during
this pregnancy? o Y

oN

TT2:_____/_____/_____
TT3:_____/_____/_____
TT4:_____/_____/_____
TT5:_____/_____/_____

oU

Is the prenatal care history reported by:

Is the child protected at birth*?


Is the immunization status reported by:

Card Recall Both Unknown

o Card o Recall o Both o Unknown

o Yes

o No

o Unknown

State reason for no or late prenatal


care:________________________________

IV. DELIVERY PRACTICES:


Place of Delivery: o Home

o Hospital/lying-in/clinic

o Other, specify: ______________________________________

If born in a hospital/lying-in/clinic, give name and address of the hospital/lying-in/clinic: __________________________________


Cord was cut using:

o Scissors o Blade

o Bamboo o Unknown o Other, specify:__________________________


Who attended the delivery? o Physician o Nurse
o Hilot

o MIdwife

o Unknown o Other, specify:________________________________________

If Hilot, was he/she trained? o Yes

o No

o Unknown

Stump treated (dressed) with: o Alcohol

o Povidone iodine

V. CLASSIFICATION AND OUTCOME:


CASE CLASSIFICATION

OUTCOME

Suspected Case

Alive

Confirmed Case

Died

Date died: ____/____/____

Unknown

185

Page 2 of 2

Case Investigation Form

Neonatal Tetanus
CASE DEFINITION/CLASSIFICATION:

Suspected Case: Any neonatal death between 3-28 days of age in which the cause of death is unknown;
or any neonate reported as having suffered from neonatal tetanus between 3-28 days of age and not
investigated.

Probable Case: Not applicable

Confirmed Case: Any neonate ( = 28 days of life) that sucks and cries normally during the first 2 days of
life, and becomes ill between 3 to 28 days of age and develops both an inability to suck and diffuse muscle
rigidity (stiffness), which may include trismus, clenched fists or feet, continuously pursed lips, and/or curved
back (opisthotonus).
OR

A neonate diagnosed as a case of tetanus by a physician.

NOTE: Neonatal tetanus case classification is based solely on clinical criteria. Any neonatal death occurring in
babies 3-28 days old with no apparent cause should be suspected as NT and evaluated according to the
above criteria. In calculating age, the day of birth is considered the first day of life (i.e., the baby is 1 day old
on the day he/she was born).
Protection at Birth (PAB) is defined as any of the following:
Regardless of interval:
2 TTV doses during the pregnancy with the youngest child, or
1 TTV dose during the pregnancy with the youngest child plus 2 doses prior to the pregnancy, or
3 TTV doses prior to the pregnancy with the youngest child

186

Page 1 of 2

Philippine Integrated Disease


Surveillance and Response

Case Investigation Form

Paralytic Shellfish Poisoning


(ICD 10 Code: T61.2)
Name of DRU:

Type: RHU

Address:

I. PATIENT
INFORMATION:

CHO Govt Hospital

Govt Laboratory
Patient Number:

Patients First Name

Private Laboratory

Middle Name

Complete Address:
Sex:
ILHZ:

Patient Admitted? Yes No Unknown

Male
Female

MM

Date Admitted/
Seen/Consult

Airport/Seaport

DD

Age:

YY

Days
Months
Years

Date of
Birth:

DD

YY

Clinic

Last Name

MM

District:

Private Hospital

MM

Date Onset of Illness

DD

YY

II. EXPOSURE HISTORY:


Specify place where suspected shellfish was harvested:____________________________________________
Yes No

Are there other members of household/community who shared the same meal?

Unknown

III. CLASSIFICATION AND OUTCOME:


FINAL CLASSIFICATION

OUTCOME

Suspected Case

Alive

Confirmed Case

Died

Date died: ____/____/____

Unknown

Name of DRU:

Type: RHU

Address:

I. PATIENT
INFORMATION:

CHO Govt Hospital

Govt Laboratory
Patient Number:

Patients First Name

Sex:
Date Admitted/
Seen/Consult

Private Laboratory

Middle Name

Complete Address:
Patient Admitted? Yes No Unknown

Private Hospital

Male
Female

MM

DD

YY

Airport/Seaport
Last Name

MM

Date of
Birth:

Clinic

DD

Date Onset of Illness

Days
Months
Years

Age:

YY

MM

DD

YY

II. EXPOSURE HISTORY:


Specify place where suspected shellfish was harvested:____________________________________________
Are there other members of household/community who shared the same meal?

Yes No

Unknown

III. CLASSIFICATION AND OUTCOME:


FINAL CLASSIFICATION

OUTCOME

Suspected Case

Alive

Confirmed Case

Died

Date died: ____/____/____

Unknown
CASE DEFINITION/CLASSIFICATION:

Suspected case: A person who develops one or more of


the following signs and symptoms after taking shellfish meal
or soup:
Sensory : paresthesias (tingling sensations on skin),
numbness (lack of sensation) of the oral mucosa and lips,
numbness of the extremities
Motor: difficulty in speaking, swallowing, or breathing,
weakness or paralysis of the extremities

Probable Case: Not applicable

Confirmed case: A suspected case in which laboratory tests (biologic or environmental) have confirmed
exposure.

LABORATORY CONFIRMATION:

Detection of saxitoxin in epidemiologically implicated


food, serum or urine of cases

(Please use the back page)

187

Page 2 of 2

Case Investigation Form

Paralytic Shellfish Poisoning


Name of DRU:

Type: RHU

Address:

I. PATIENT
INFORMATION:

CHO Govt Hospital

Govt Laboratory
Patient Number:

Patients First Name

Private Laboratory

Middle Name

Complete Address:
Sex:
MM

Date Admitted/
Seen/Consult

Male
Female

Airport/Seaport

DD

Age:

YY

Days
Months
Years

Date of
Birth:

DD

YY

Clinic

Last Name

MM

District:
ILHZ:
Patient Admitted? Yes No Unknown

Private Hospital

MM

Date Onset of Illness

DD

YY

II. EXPOSURE HISTORY:


Specify place where suspected shellfish was harvested:____________________________________________
Yes No

Are there other members of household/community who shared the same meal?

Unknown

III. CLASSIFICATION AND OUTCOME:


FINAL CLASSIFICATION

OUTCOME

Suspected Case

Alive

Confirmed Case

Died

Date died: ____/____/____

Unknown

Name of DRU:

Type: RHU

Address:

I. PATIENT
INFORMATION:

CHO Govt Hospital

Govt Laboratory
Patient Number:

Patients First Name

Sex:
Date Admitted/
Seen/Consult

Private Laboratory

Middle Name

Complete Address:
Patient Admitted? Yes No Unknown

Private Hospital

MM

Male
Female
DD

YY

Airport/Seaport
Last Name

MM

Date of
Birth:

DD

Date Onset of Illness

MM

Specify place where suspected shellfish was harvested:____________________________________________


Yes No

III. CLASSIFICATION AND OUTCOME:


FINAL CLASSIFICATION

OUTCOME

Suspected Case

Alive

Confirmed Case

Died
Unknown

188

Date died: ____/____/____

Days
Months
Years

Age:

YY

II. EXPOSURE HISTORY:

Are there other members of household/community who shared the same meal?

Clinic

Unknown

DD

YY

Page 1 of 2

Philippine Integrated Disease


Surveillance and Response

Case Investigation Form

Rabies
(ICD 10 Code: A82)
Name of DRU:

Type: RHU

CHO Govt Hospital

Govt Laboratory

Address:

I. PATIENT
INFORMATION:

Patient Number:

Patients First Name

Middle Name

Complete Address:
Male
Female

Sex:
MM

Date Admitted/
Seen/Consult

DD

DD

Age:

YY

Days
Months
Years

Date of
Birth:
YY

Clinic

Airport/Seaport
Last Name

MM

District:
ILHZ:
Patient Admitted? Yes No Unknown

Private Hospital

Private Laboratory

Date Onset of
Illness

MM

DD

YY

II. EXPOSURE HISTORY:


Type of exposure: bite saliva scratch
Type of animal:

dog cat

Lab. diagnosis done?


Animal status:

Yes

domestic

Outcome of biting animal: alive

bat

Unknown

Other, specify _______________

Other, specify_______________________

No

Unknown

stray

wild

died

killed intentionally

If Yes, result: _______________________________________


Other, specify _______________
Place of Incidence: ________________________________________

III. VACCINATION HISTORY:


Animal vaccination history:

Patient History:

Vaccinated

Wound cleaned?:

Unvaccinated

Patient given RIG?: Yes No Unknown

Unknown

(RIG is Rabies Immunoglobulin)

Yes No Unknown

Patient given rabies vaccine?: Yes No Unknown

IV. CLASSIFICATION AND OUTCOME:


FINAL CLASSIFICATION

OUTCOME

Suspected Case

Alive

Probable Case

Died

Confirmed Case

Unknown

Date died: ____/____/____

CASE DEFINITION/CLASSIFICATION:

LABORATORY CONFIRMATION:

Suspected Case: A person presenting with an acute


neurological syndrome (encephalitis) dominated by forms
of hyperactivity (furious rabies) or paralytic syndromes
(dumb rabies) that progresses towards coma and death,
usually by respiratory failure, within 7 to 10 days after the
first symptom if no intensive care is instituted.

One or more of the following:

Probable case: A suspected case plus history of contact


with suspected rabid animal.

Note: Bites or scratches from a suspected animal can usually be


traced back in the patient medical history. The incubation period
may vary from days to years but usually falls between 30 and 90
days.

Confirmed case: A suspected case that is laboratory


confirmed.

Detection of rabies viral antigens by direct fluorescent


antibody (FA) in clinical specimens, preferably brain
tissue (collected post mortem);
Detection by FA on skin or corneal smear (collected
ante mortem);
FA positive after inoculation of brain tissue, saliva or
CSF in cell culture, in mice or in suckling mice;
Detectable rabies -neutralizing antibody titer in the CSF
of an unvaccinated person;
Identification of viral antigens by PCR on fixed tissue
collected post mortem or in a clinical specimen (brain
tissue or skin, cornea or saliva);
Isolation of rabies virus from clinical specimens and
confirmation of rabies viral antigens by direct fluorescent antibody testing.

(Please use the back page)

189

Page 2 of 2

Case Investigation Form

Rabies
Name of DRU:

Type: RHU

CHO Govt Hospital

Govt Laboratory

Address:

I. PATIENT
INFORMATION:

Patient Number:

Patients First Name

Private Laboratory

Middle Name

Complete Address:
Male
Female

Sex:
MM

Date Admitted/
Seen/Consult

DD

Airport/Seaport

DD

Age:

YY

Days
Months
Years

Date of
Birth:
YY

Clinic

Last Name

MM

District:
ILHZ:
Patient Admitted? Yes No Unknown

Private Hospital

Date Onset of
Illness

MM

DD

YY

II. EXPOSURE HISTORY:


Type of exposure: bite saliva scratch
Type of animal:

dog cat

Lab. diagnosis done?


Animal status:

Yes

domestic

Outcome of biting animal: alive

Unknown

Other, specify _______________

bat

Other, specify_______________________

No

Unknown

If Yes, result: _______________________________________

stray

wild

died

killed intentionally

Other, specify _______________


Place of Incidence: ________________________________________

III. VACCINATION HISTORY:


Animal vaccination history:

Patient History:

Vaccinated

Wound cleaned?:

Unvaccinated

Patient given RIG?: Yes No Unknown

Unknown

(RIG is Rabies Immunoglobulin)

Yes No Unknown

Patient given rabies vaccine?: Yes No Unknown

IV. CLASSIFICATION AND OUTCOME:


FINAL CLASSIFICATION

OUTCOME

Suspected Case

Alive

Probable Case

Died

Confirmed Case

Unknown

190

Date died: ____/____/____

Philippine Integrated Disease


Surveillance and Response

Case Investigation Form

Adverse Event Following Immunization


Name of DRU:

Type : RHU CHO Govt Hospital Private Hospital Clinic

Address:

I. PATIENT
INFORMATION:

Govt Laboratory Private Laboratory Airport/Seaport


Patient Number: Patients First Name

Middle Name

Last Name

Complete Address:

MM

Male
Sex:
Female
District:

DD

YYYY

Age:

Days
Months
Years

Date of
Birth:

ILHZ:

Patient Admitted? Yes No Unknown

Date Admitted/ Seen/


Consult

MM

DD

Address of hospital/health facility:


MM

Date next higher level


notified:

Name of hospital/health facility:

Date onset of
illness
DD

YYYY

TIME (hh:min:sec)
___:___:___ AM/PM

MM

YYYY

DD

YYYY

Date of Investigation:

MM

DD

YYYY

TIME (hh:min:sec)
____:____:____ AM / PM

Interval from onset of illness to notification: ______days _____hours

TIME (hh:min:sec)
___:___:___ AM/PM

Interval from notification to investigation:

______days _____hours

II. TYPE OF SERIOUS AEFI (See back page for descriptions): check all that apply
1. LOCAL
Injection site abscess
Lymphadenitis
Severe local reaction (redness
and/or swelling centered at the
site of injection)

2. CENTRAL NERVOUS SYSTEM


Acute paralysis
Encephalopathy
Seizures

4. OTHER SEVERE and UNUSUAL


EVENTS OCCURRING WITHIN 4 WEEKS
AFTER IMMUNIZATION AND NOT
COVERED UNDER ITEM NOS. 1, 2 or 3

3. OTHER ADVERSE EVENTS


Anaphylactoid reaction
Anaphylactic shock
Neuritis
Disseminated BCG infections
Hypotensive-hyporesponsive
episode (shock collaspe)

Osteitis/osteomyelitis
Persistent screaming
(inconsolable continuous
crying lasting at least 3 hours)
Sepsis
Thrombocytopenia
Toxic shock syndrome

Any death of a vaccine recipient temporarily linked (within 4 weeks) to immunization,


where no other clear cause of death can be established.
Other severe/unusual event (specify):_____________________________________________

III. MOST RECENT VACCINATION HISTORY:


Date of vaccination:____/____/____
Time of vaccination: ____:____: ____ AM PM
Name of vaccinator:______________________________ Vaccinator : Physician Nurse Midwife Other___________________
Place of vaccination: Health center BHS Public hospital
Private hospital Private clinic Outreach
Other (specify): ___________________________________
SUSPECTED
VACCINE/S
(BCG, DPT, OPV,
Measles, HBV, others)

DETAILS OF VACCINE
Dose
Number/vial

Lot/Batch
number

Manufacturer

DETAILS OF DILUENT IF USED

Expiry date

Dose
Number/
vial

Lot/Batch
number

Manufacturer

Expiry date

Did the patient receive any vaccination within 4 weeks prior to this adverse event? Y N U (If YES, complete the information below).
VACCINE/S
(BCG, DPT, OPV, Measles,
HBV, others)

DETAILS OF VACCINE
Dose number
(single/multiple)

Lot/Batch
number

Manufacturer

Expiry date

Date given

IV. MEDICAL HISTORY:


Did the patient take other medications at the time of vaccination?

Birth defects: Y N U

Y N U

Family history of similar event? Y N U

If YES, what were these medications?

_______________________________________________________
Does the patient had history of similar reaction? Y N U

Is the patient suffering from other medical conditions?


Y N U

Does the patient had history of allergy? Y N U

If YES, what are these conditions? _______________________

If YES, what are these allergies?_____________________________

_____________________________________________________

CASE DEFINITION:

Suspected AEFI case: Any individual that experience a serious condition any time after he or she received an immunization and is considered by a health worker (e.g., midwife, nurse, physician) to be possibly related to that immunization.

177

Page 2 of 2

Case Investigation Form

Adverse Event Following Immunization


V. CAUSALITY ASSESSMENT AND FINAL DIAGNOSIS: (TO BE FILLED UP AFTER CLASSIFICATION BY THE BOARD)
What is the cause of AEFI?
Program-related

Vaccine-related

Coincidental
Unknown
Injection Reaction
Final diagnosis:___________________________________

If program-related, was it due to


non-sterile injection
vaccine prepared incorrectly
wrong administration technique
improper vaccine transport or storage
Other, specify______________________________________

VI. OUTCOME:
Outcome: Alive

Patient sustained disability? Yes No Unknown


If YES, specify type of disability:__________________________________________

Died

Date died: ____/____/____

Unknown
Definition of Terms:
An adverse event following immunization (AEFI) is defined as a medical incident that takes place after an immunization, causes concern,
and is believed to be caused by immunization.
A cluster of AEFI is defined as two or more cases of the same adverse event related in time, place or vaccine administered.
Serious medical condition is defined as those that are life-threatening and those that result in hospitalization (or prolonged hospitalization),
disability (or have the potential to result in disability) or death.
LOCAL ADVERSE EVENTS:
Injection-Site Abscess: Occurrence of a fluctuant or draining fluid-filled lesion at the site of injection with or without fever.
Lymphadenitis (includes suppurative lymphadenitis): Occurrence of either: at least one lymph node, 1.5 cm in size (one adult finger
width) or larger; or a draining sinus over a lymph node. Almost exclusively caused by BCG and then occurring within 2 to 6 months after
receipt of BCG vaccine, on the same side as inoculation (mostly axillary).
Severe local reaction: Redness and/or swelling centered at the site of injection and one or more of the following: swelling beyond the
nearest joint; pain, redness and swelling of more than 3 days duration; or requires hospitalization.
CENTRAL NERVOUS SYSTEM ADVERSE EVENTS:

Acute Paralysis

Acute onset of flaccid paralysis within 4 to 30 days of receipt of oral polio-virus vaccine (OPV), or within 4 -75 days after contact with
a vaccine recipient, with neurological deficits remaining 60 days after onset, or death.
Guillain-Barr Syndrome (GBS): Acute onset of rapidly progressive, ascending, symmetrical flaccid paralysis, without fever at onset of
paralysis and with sensory loss. Cases are diagnosed by cerebrospinal fluid (CSF) investigation showing dissociation between cellular
count and protein content. GBS occurring within 30 days after immunization should be reported.

Encephalopathy: Encephalopathy is an acute onset of major illness temporally linked with immunization and characterized by any two of
the following three conditions: Seizures; Severe alteration in level of consciousness lasting for one day or more; and Distinct change in behavior lasting one day or more. Cases occurring within 72 hours after vaccination should be reported.
Encephalitis: Encephalitis is characterized by encephalopathy and signs of cerebral inflammation and, in many cases, CSF pleocytosis
and/or virus isolation. Any encephalitis occurring within 1 to 4 weeks following immunization should be reported.
Meningitis: Acute onset of major illness with fever, neck stiffness/positive meningeal signs (Kernig, Brudzinski). Symptoms may be subtle to
similar to those of encephalitis. CSF examination is the most important diagnostic measure: CSF pleocytosis and/or detection of microorganism (Gram stain or isolation).
Seizures: Seizures lasting from several minutes to more than 15 minutes and not accompanied by focal neurological signs or symptoms.
Febrile Seizures or Afebrile Seizures. Onset is usually 0 to 2 days.

OTHER ADVERSE EVENTS:

Anaphylactoid Reaction (acute hypersensitivity reaction): Exaggerated acute reaction, occurring within 2 hours after immunization,
characterized by one or more of the following: (1) wheezing and shortness of breath due to bronchospasm; (2) laryngospasm/laryngeal
edema; (3) one or more skin manifestations, e.g. hives, facial edema, or generalized edema.
Anaphylactic Shock: Circulatory failure (e.g. alteration of the level of consciousness, low arterial blood pressure, weakness or absence of
peripheral pulses, cold extremities secondary to reduced peripheral circulation, flushed face and increased perspiration) with or without
bronchospasm and/or laryngospasm/laryngeal edema leading to respiratory distress occurring immediately (0 to1 hr) after immunization.
Neuritis: Dysfunction of nerves supplying the arm/shoulder/gluteal area without other involvement of nervous system. A deep steady, often
severe aching pain in the shoulder and upper arm or gluteal area followed in days or weakness by weakness and wasting in arm/shoulder/
gluteal muscles. Sensory loss may be present, but is less prominent. May present on the same or the opposite side to the injection and
sometimes affects both arms or gluteal area. Onset is usually 2 to 28 days.
Disseminated BCG infection: Disseminated infection occurring within 1 to 12 months after BCG vaccination and confirmed by isolation of
Mycobacterium bovis BCG strain.
Hypotensive-Hyporesponsive Episode (shock collapse): Sudden onset of paleness, decreased level or loss of responsiveness, decreased level or loss of muscle tone (occurring within 24 hours of vaccination). The episode is transient and self -limiting.
Osteitis/Osteomyelitis: Inflammation of the bone either due to BCG immunization (occurring within 8 to 16 months after immunization) or
caused by other bacterial infection.
Persistent Screaming: Inconsolable continuous crying lasting at least 3 hours accompanied by high-pitched screaming. Onset 0 to 24 hrs.
Sepsis: Acute onset of severe generalized illness due to bacterial infection and confirmed by positive blood culture.
Thrombocytopenia: Platelet count of 100,000 cells or less per mm3. Onset is 15 to 35 days.
Toxic-Shock Syndrome: Abrupt onset of fever, vomiting and watery diarrhea within a few hours of immunization, often leading to death
within 24-48 hours.

178

You might also like